Schizophrenia

EQS-News: Newron presents 2023 financial results and provides 2024 outlook

Retrieved on: 
Wednesday, April 10, 2024
Psychosis, Schizophrenia, Clozapine, XETRA, Patient, CNS, Business development, Peripheral nervous system, Psychedelic literature, Safety, TRS, PANSS, EIB, Canadian International Council, Pharmaceutical industry

Milan, Italy, March 19, 2024, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2023, and provided an outlook for 2024.

Key Points: 
  • Milan, Italy, March 19, 2024, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2023, and provided an outlook for 2024.
  • Results from the first 100 patients to complete six months (30 weeks) of treatment with evenamide were reported in January, followed by results in February 2023 from the same 100-person cohort at the one-year (52 weeks) timepoint.
  • These data were further strengthened, post-period in January 2024, with the final results from study 015 reviewing all study participants after one year of treatment.
  • Patient enrollment has completed and results from this study are expected in April 2024.

EQS-News: Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement

Retrieved on: 
Wednesday, April 10, 2024
EIB, Peripheral nervous system, Patient, CNS, Schizophrenia, XETRA, European Investment Bank, BofA Securities, Pharmaceutical industry

Under the amendment, repayment of tranches one to three (out of a total of five) of the financing agreement with due dates from June 2024 to April 2025 will be shifted substantially, with tranche one now scheduled for November 25, 2025, tranche two for April 2026 and tranche three for June 2026.

Key Points: 
  • Under the amendment, repayment of tranches one to three (out of a total of five) of the financing agreement with due dates from June 2024 to April 2025 will be shifted substantially, with tranche one now scheduled for November 25, 2025, tranche two for April 2026 and tranche three for June 2026.
  • The due dates for tranches four and five will stay unchanged.
  • On the amended tranches, Newron will start paying the agreed interest rates.
  • Details of the 2018 loan agreement can be found in Newron’s 2022 Annual Report which is posted on its website.

EQS-News: Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)

Retrieved on: 
Wednesday, April 10, 2024
SIRS, Schizophrenia, Clozapine, XETRA, Incidence, Patient, CNS, Peripheral nervous system, Safety, TRS, Schizophrenia International Research Society, Pharmaceutical industry

The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.

Key Points: 
  • The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.
  • As previously announced by Newron, the study showed that the addition of evenamide to antipsychotics was well tolerated, with low incidence of treatment-emergent adverse events.
  • Treatment with evenamide was associated with sustained, clinically significant benefit that increased throughout the one-year course of treatment.
  • Study 008A is a four-week, randomized, double-blind and placebo-controlled study assessing the efficacy, tolerability, and safety of evenamide (30 mg bid).

Brain & Behavior Research Foundation Awards Distinguished Investigator Grants Valued at $1 Million to 10 Scientists Pursuing Innovative Mental Health Research

Retrieved on: 
Thursday, April 4, 2024
Depression, Patient, Mitochondrion, Doctor of Science, Harvard University, Therapy, Research, Risk, Mental health, University of Pittsburgh, Brain, DSM-IV codes, Brown University, Cannabis, Memory, Safety, Spectrum, Mitophagy, Schizophrenia, Hippocampus, Bipolar disorder, Anxiety, Learning, University, Psychopathology, Cerebrospinal fluid, University of California, Distinguishing, PET, Biomarker, Hope, Baylor College of Medicine, Behavior, AMPA, Fragile X syndrome, PTSD, Pharmaceutical industry

New York, April 04, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced it is awarding Distinguished Investigator Grants valued at $1 million to 10 senior-level scientists who are conducting innovative projects in neurobiological and behavioral research.

Key Points: 
  • New York, April 04, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced it is awarding Distinguished Investigator Grants valued at $1 million to 10 senior-level scientists who are conducting innovative projects in neurobiological and behavioral research.
  • By funding transformative research focused on new ways to prevent, diagnose, and treat psychiatric disorders, our Distinguished Investigator Grants are encouraging established scientists to continue advancing our understanding of mental illness and disorders of brain and behavior,” says Jeffrey Borenstein, M.D., President and CEO of the Brain & Behavior Research Foundation.
  • The ground-breaking work of the Distinguished Investigator Grant recipients will bring hope and healing to people and families impacted by mental illness.
  • We applaud these scientists for their extraordinary dedication, innovation, and leadership.”
    Recipients of the Distinguished Investigator Grants are full professors at research institutions in the United States and abroad.

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia

Retrieved on: 
Wednesday, April 3, 2024
Depression, Neurology, Schizophrenia, Patent, CFO, Opioid use disorder, OTCQB

The USPTO has issued U.S. Patent No.

Key Points: 
  • The USPTO has issued U.S. Patent No.
  • 11,793,801 entitled, “Treatment of Pain and Neurological Conditions”.
  • The patent is directed towards the use of a compound and composition and/or dosage form for treating pain, depression, and schizophrenia.
  • Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., and President, and Chairman of BioCorRx Pharmaceuticals Inc., commented, “The patented invention may offer a novel approach to reducing the severity of withdrawal symptoms for opioid use disorder compared to current standards of care."

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Retrieved on: 
Thursday, March 28, 2024
SIRS, Central nervous system, CNS, Schizophrenia, Poster, Schizophrenia International Research Society, Annual general meeting, Pharmaceutical industry

CUPERTINO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at the 2024 Schizophrenia International Research Society (SIRS) Annual Meeting, to be held April 3-7, 2024, in Florence, Italy.

Key Points: 
  • CUPERTINO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at the 2024 Schizophrenia International Research Society (SIRS) Annual Meeting, to be held April 3-7, 2024, in Florence, Italy.
  • Details for the Oral and poster presentations can be found below:
    Presentation Title: Brilaroxazine Phase 3 Recover Trial in Acute Schizophrenia Supports Efficacy, Safety, and Effects on Neuroinflammation
    Oral Presentation Date and Time: Thursday, April 4, 2024 at 10:25 – 10:45 AM CET
    Poster Presentation Date and Time: Thursday, April 4, 2024 at 12:00 – 2:00 PM CET

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Depression, Eli Lilly, Major depressive disorder, Patient, Bristol Myers Squibb, PureTech Health, PRTC, Therapy, Creativity, Disorder, General counsel, CNS, Life, DSM-IV codes, Pleasure, Pharmacokinetics, Interim, Third Rock Ventures, U.S. FDA, Schizophrenia, KarXT, Teva Pharmaceuticals, ARCH Venture Partners, Merck, Anxiety, Merck & Co., Research and development, FDA, Lymphatic system, Hepatotoxicity, Sirna Therapeutics, Generalized anxiety disorder, Growth, Neuropsychiatry, Partner, Multimedia, Eli Lilly and Company, Probability, Liver, Medicine, Pharmaceutical industry

Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.

Key Points: 
  • Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.
  • Under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.
  • Eric Elenko, Ph.D., a PureTech co-founder and current Chief Innovation Officer, has been promoted to the role of President of PureTech.
  • Daphne Zohar, the Chief Executive Officer of Seaport, is the founder and former CEO of PureTech Health where she also co-founded Karuna Therapeutics.

Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines

Retrieved on: 
Tuesday, April 9, 2024
Mental Health, Health, Neurology, General Health, Pharmaceutical, Biotechnology, Generalized anxiety disorder, Depression, Eli Lilly, U.S. FDA, Schizophrenia, KarXT, Major depressive disorder, ARCH Venture Partners, Patient, CNS, Anxiety, Bristol Myers Squibb, PureTech Health, DSM-IV codes, Pleasure, Neuropsychiatry, Research and development, Therapy, Pharmacokinetics, Partner, Disorder, Third Rock Ventures, Probability, FDA, Lymphatic system, Hepatotoxicity, Liver, Medicine, Pharmaceutical industry

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.
  • The round was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder PureTech Health.
  • Seaport is advancing a clinical-stage pipeline of novel neuropsychiatric medicines powered by its proprietary Glyph™ Technology Platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms.
  • I am eager to support Seaport as an investor and board member as the team continues to advance its clinical-stage pipeline of novel therapeutics.”

Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)

Retrieved on: 
Monday, April 8, 2024
Mental Health, Research, Neurology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, SIRS, Schizophrenia, Medication, Clozapine, XETRA, Incidence, Patient, CNS, Peripheral nervous system, Safety, TRS, Schizophrenia International Research Society, Pharmaceutical industry

The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.

Key Points: 
  • The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.
  • As previously announced by Newron, the study showed that the addition of evenamide to antipsychotics was well tolerated, with low incidence of treatment-emergent adverse events.
  • Treatment with evenamide was associated with sustained, clinically significant benefit that increased throughout the one-year course of treatment.
  • Study 008A is a four-week, randomized, double-blind and placebo-controlled study assessing the efficacy, tolerability, and safety of evenamide (30 mg bid).

Lost for words? Research shows art therapy brings benefits for mental health

Retrieved on: 
Tuesday, April 9, 2024
Observational study, Depression, Health, First Nations, Mental health, Grief, Schizophrenia, Acute stress disorder, Environment, Mental, Post-traumatic stress disorder, Risk, Eating, Patient, Journal, Trauma, Research, Child, Magic, Anxiety, Cancer, Fatigue, Sculpture, Adolescence, Drawing, Regulation, Safety, Spectrum, Art therapy, Emotion, Palliative care, Dementia, Nursing

Art therapy uses creative processes, primarily visual art such as painting, drawing or sculpture, with a view to improving physical health and emotional wellbeing.

Key Points: 
  • Art therapy uses creative processes, primarily visual art such as painting, drawing or sculpture, with a view to improving physical health and emotional wellbeing.
  • Art therapy can be used to support treatment for a wide range of physical and mental health conditions.
  • In a study published this week in the Journal of Mental Health, we found art therapy was associated with positive outcomes for children and adolescents in a hospital-based mental health unit.

An option for those who can’t find the words

  • Where possible, after finishing an artwork, a person can explore the meaning of their work with the art therapist, translating unspoken symbolic material into verbal reflection.
  • However, as the talking component is less central to the therapeutic process, art therapy is an accessible option for people who may not be able to find the words to describe their experiences.
  • Art therapy has also been linked to improved outcomes for people with a range of physical health conditions.

Our research

  • While most care takes place in the community, a small proportion of young people require care in hospital to ensure their safety.
  • However, these “restrictive practices” are associated with negative effects such as post-traumatic stress for patients and health professionals.
  • Read more:
    'An arts engagement that's changed their life': the magic of arts and health

    Our research looked at more than six years of data from a child and adolescent mental health hospital ward in Australia.

  • Confirming the effect of a therapeutic intervention requires controlled clinical trials where people are randomly assigned one treatment or another.
  • Although ours was an observational study, randomised controlled trials support the benefits of art therapy in youth mental health services.

What do young people think?

  • In previous research we found art therapy was considered by adolescents in hospital-based mental health care to be the most helpful group therapy intervention compared to other talk-based therapy groups and creative activities.
  • In research not yet published, we’re speaking with young people to better understand their experiences of art therapy, and why it might reduce distress.

A promising area


The burgeoning research showing the benefits of art therapy for both physical and especially mental health highlights the value of creative and innovative approaches to treatment in health care. There are opportunities to expand art therapy services in a range of health-care settings. Doing so would enable greater access to art therapy for people with a variety of physical and mental health conditions.

  • She has received funding from the Health Education and Training Institute (HETI) for the Mental Health Research Award.
  • Iain Perkes works for the University of New South Wales and the Sydney Children's Hospitals Network which is part of NSW Health.
  • He is affiliated with Neuroscience Research Australia (NeuRA) and the Health Education and Training Institute (HETI, NSW Health).